Active constituents: The dried fruit of milk thistle contain a
flavonoid complex known as silymarin. This constituent is
responsible for the medical benefits of the plant.1 Silymarin is made up of three
parts: silibinin, silidianin, and silicristin. Silibinin is the most active and is largely
responsible for the benefits attributed to silymarin.2
Milk thistle extract may protect the cells of the liver by blocking the entrance of harmful
toxins and helping remove these toxins from the liver cells.3 4 As with
other bioflavonoids, silymarin is a powerful
antioxidant.5 Silymarin has also been shown to regenerate injured liver
cells.6 Recent studies have shown that silymarin has the ability to block fibrosis,
a process that contributes to the eventual development of cirrhosis in people with inflammatory liver conditions
secondary to diseases such as alcohol abuse or hepatitis.7
Milk thistle extract is most commonly recommended to counteract the harmful actions of
alcohol on the liver. Double-blind trials indicate that it helps the liver return to a healthy
state once a person stops drinking.8 9 Some trials suggest it may
improve quality of life and even life expectancy in people with liver cirrhosis.10
11 However, another trial found no effect in cirrhosis patients.12 Milk
thistle alters bile makeup, thereby potentially reducing risk of gallstones.13 However, this needs to be verified by
human clinical trials. Milk thistle extract has been shown to protect the liver from the
potentially damaging effect of drugs used to treat
schizophrenia and other forms of psychosis.14 However, one trial found that it
did not protect the liver from the potentially harmful effects of the drug Cognex (tacrine hydrochloride) used to treat early-stage Alzheimer’s disease. 15
References:
1. Wagner H, Horhammer L, Munster R. The chemistry of silymarin
(silybin), the active principle of the fruits of Silybum marianum (L.) Gaertn.
Arzneim-Forsch Drug Res 1968;18:688–96.
2. Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of
flavonolignans from Silybum marianum fruits. Planta Medica
1984;50:248–50.
3. Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin
uptake in the perfused rat liver. Arzneim-Forsch Drug Res 1980;30:452–4.
4. Tuchweber B, Sieck R, Trost W. Prevention by silibinin of phalloidin
induced hepatotoxicity. Toxicol Appl Pharmacol 1979;51:265–75.
5. Feher J, Lang I, Deak G, et al. Free radicals in tissue damage in
liver diseases and therapeutic approach. Tokai J Exp Clin Med
1986;11:121–34.
6. Sonnenbichler J, Zetl I. Stimulating influence of a flavonolignan
derivative on proliferation, RNA synthesis and protein synthesis in liver cells. In
Assessment and Management of Hepatobiliary Disease, ed. L Okolicsanyi, G Csomos, G
Crepaldi. Berlin: Springer-Verlag, 1987, 265–72.
7. Schuppan D, Strösser W, Burkard G, Walosek G. Legalon®
lessens fibrosing activity in patients with chronic liver diseases. Zeits
Allgemeinmed 1998;74:577–84.
8. Salmi HA, Sama S. Effect of silymarin on chemical, functional and
morphological alterations of the liver. Scand J Gastroenterol
1982;17:517–21.
9. Leng-Peschlow E. Alcohol-related liver diseases-use of Legalon®.
Z Klin Med 1994;2:22–7.
10. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled
trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol
1989;9:105–13.
11. Velussi M, Cernogoi AM, De Monte A, et al. Long-term (12 months)
treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous
insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatology
1997;26:871–9.
12. Pares A, Plancs R, Torres M, et al. Effects of silymarin in alcoholic
patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and
multicenter trial. J Hepatol 1998;28:615–21.
13. Nassuato G, Iemmolo RM, Strazzabosco M, et al. Effect of silibinin on
biliary lipid composition. Experimental and clinical study. J Hepatol
1991;12:290–5.
14. Palasciano G, Portinascasa P, Palmieri V, et al. The effect of
silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with
psychotropic drugs. Curr Ther Res 1994;S5:S37–45.
15. Allain H, Schück S, Lebreton S, et al. Aminotransferase levels
and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dementia
Geriatr Cogn Disorders 1999;10:181–5.
16. Brown DJ. Herbal Prescriptions for Better Health. Rocklin,
CA: Prima Publishing, 1996, 151–8.
17. Reyes H. The spectrum of liver and gastrointestinal disease seen in
cholestasis of pregnancy. Gastroert Clin N Am 1992;21:905–21.
18. Adverse Drug Reactions Advisory Committee. An adverse reaction to the
herbal medication milk thistle (Silybum marianum). MJA
1999;170:218–9.